Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 9/20 | 0.50 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21090745 | 0.83 | CTSD (0.50) | CTSDHCAR1ALOX15GAAMEN1 | |
| SCHEMBL21090746 | 0.80 | CTSD (0.47) | CTSDHCAR1ALOX15GAAMEN1 | |
| SCHEMBL21089924 | 0.76 | KDM4E (0.61) | CTSDMEN1KMT2AAPPKDM4E | |
| SCHEMBL21064290 | 0.74 | CTSD (0.42) | CTSDHCAR1ALOX15GAAMEN1 | |
| SCHEMBL9953326 | 0.67 | PI4KA (0.45) | CTSDHCAR1MEN1KMT2AATM | |
| SCHEMBL9952794 | 0.67 | HCAR1 (0.41) | CTSDHCAR1MEN1KMT2AATM | |
| SCHEMBL22736790 | 0.67 | TSHR (0.40) | CTSDALOX15GAATSHR | |
| SCHEMBL12177192 | 0.65 | PARG (0.41) | MEN1KMT2AAPPTSHRKDM4E | |
| SCHEMBL6922422 | 0.64 | ACHE (0.35) | — | |
| SCHEMBL24463605 | 0.64 | KDM4E (0.57) | GAAKDM4EALDH1A1HTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. | 2020-11-26 | — | — | US | disclosed |
| WO-2019112719-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | CTSD 4473/4885HCAR1 3320/4885ALOX15 3883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.